TMVP1448, a novel peptide improves detection of primary tumors and metastases by specifically targeting VEGFR-3.
Biomed Pharmacother
; 177: 116980, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38908201
ABSTRACT
Lymphangiogenesis at primary tumor and draining lymph nodes plays a pivotal role in tumor metastasis, which has been demonstrated to be regulated by the vascular endothelial growth factor receptor 3 (VEGFR-3) pathway. However, the effect of molecular imaging peptides, which specifically bind VEGFR-3, in tracing tumors remains unclear. We prepared a novel peptide, TMVP1448, with high-affinity to VEGFR-3. The dissociation constant (KD) of TMVP1448 with VEGFR-3 was 7.07 ×10-7 M. In vitro cellular assay showed that TMVP1448 could bind specifically with VEGFR-3. Near infrared imaging results showed that Cy7-TMVP1448 was able to accurately trace primary and metastatic cancers, and PET/CT results showed that [68Ga]Ga-DOTA-TMVP1448 was superior to commonly used radiotracers 18F-FDG. Additionally, no significant negative effect of TMVP1448 was found in mice. Our results suggested that TMVP1448 had great potential for future clinical applications in fluorescence imaging and nuclear imaging of tumors.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Péptidos
/
Receptor 3 de Factores de Crecimiento Endotelial Vascular
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Biomed Pharmacother
/
Biomed. pharmacother
/
Biomedicine & pharmacotherapy
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Francia